NCT05184322View on ClinicalTrials.gov

XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

April 12, 2022

Primary Completion Date

July 13, 2024

Study Completion Date

March 25, 2025

Conditions
ObesityType 2 Diabetes Mellitus
Interventions
DRUG

T2026

Once daily for 15 days.

DRUG

Placebo

Once daily for 15 days.

DRUG

Oral ecnoglutide tablet

Once daily for 6 weeks.

DRUG

Oral ecnoglutide tablet

Once daily and titrated up in concentration to once every week during maintenance period.

DRUG

Oral ecnoglutide tablet

Once daily for 15 days.

DRUG

Oral ecnoglutide tablet

Once daily for 15 days.

DRUG

Oral ecnoglutide tablet

Once daily for 15 days.

DRUG

Oral ecnoglutide tablet

Once daily for 15 days.

DRUG

T2026

Once daily for 6 weeks.

DRUG

Placebo

Once daily for 6 weeks.

DRUG

T2026

Once daily to once weekly for 12 weeks.

DRUG

Placebo

Once daily to once weekly for 12 weeks.

Trial Locations (1)

4006

Q-Pharm Pty Ltd (AKA Nucleus Network Brisbane), Herston

All Listed Sponsors
collaborator

Hangzhou Sciwind Biosciences Co., Ltd.

INDUSTRY

collaborator

Sciwind Biosciences USA Co., Ltd.

INDUSTRY

lead

Sciwind Biosciences APAC CO Pty. Ltd.

INDUSTRY